Tumor Mutations and VTE Risk – New Insights from a 12,500-Patient Cancer Study – JTH
Journal of Thrombosis and Haemostasis (JTH) shared a post on LinkedIn about a recent article by Naomi Cornish et al, adding:
”Associations of Tumor Somatic Mutations with Cancer-Associated Venous Thromboembolism
Analysis of 12,507 cancer patients reveals that somatic mutations in CDKN2A, KRAS, PCDH15, and TP53 significantly increase VTE risk, while high tumor mutational burden is protective, offering novel insights into cancer-associated thrombosis pathophysiology and future risk prediction tools.”
Title: Associations of tumor somatic mutations with cancer-associated venous thromboembolism
Authors: Naomi Cornish, Rebecca Ward, Matthew T. Warkentin, Chrissie Thirlwell, Andrew D. Mumford, Sarah K. Westbury, Philip C. Haycock
Read the Full Article on JTH

Stay updated on all scientific advances with Hemostasis Today.
-
Apr 6, 2026, 16:31Wolfgang Miesbach: New Real-World Data Reveal Ongoing Burden in Moderate-to-Severe Haemophilia A
-
Apr 6, 2026, 16:26Heghine Khachatryan։ Targeting High Risk Antiphospholipid Syndrome in Pregnancy with Hydroxychloroquine
-
Apr 6, 2026, 16:21Anand Padmanabhan: A New Concise Nutshell Review of MGTS as an Emerging Thrombophilia
-
Apr 6, 2026, 16:20Satyam Arora: Why Are We Transfusing Kids in India?
-
Apr 6, 2026, 16:17Jim Hoffman: Extracorporeal Blood Purification as an Alternative to IVIG and Transfusion in Autoimmune Disease
-
Apr 6, 2026, 16:16Ala Eddin Sagar: What Changed in the New Sepsis Guidelines 2026
-
Apr 6, 2026, 16:13Simon Senanu: Hypersegmented Neutrophils – A Classic Sign of Megaloblastic Anemia
-
Apr 6, 2026, 16:05Peter Bou Dib: Understanding von Willebrand Factor in Bleeding and Thrombotic Disorders
-
Apr 6, 2026, 15:30Rare Diseases, Plasma-Derived Medicines and the Elephant in the Room – Part 3